INDP | Indaptus Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.4343 - 1.5947
52 Week Range	1.2040 - 4.08
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	18,136
Average Volume	13,324
Shares Outstanding	10,196,900
Market Cap	15,907,164
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-08-04

Valuation
Profitability
Growth
Health
P/E Ratio	-0.84
Forward P/E Ratio	-0.95
EPS	-1.86
1YR Price Target	8.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	INDP

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

INDP's peers: ABIO, BCDA, NTRB, CADL, CRDL, ABVC, EDSA, FBIOP, FBRX, RZLT, TPST, CMRA, KTTA, BTTX, QNRX, LGVN, RNXT, VRAX, BWV, REVB, HILS, KPRX, ANEB, ZIVO, MTCR, ASMB, LIXT, NLSP, NNVC, ORGS, QLGN, TTNP, MLEC

*Chart delayed

Analyzing fundamentals for INDP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see INDP Fundamentals page.

Watching at INDP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on INDP Technicals page.